Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
Winokur P, Gayed J, Fitz-Patrick D, Thomas SJ, Diya O, Lockhart S, Xu X, Zhang Y, Bangad V, Schwartz HI, Denham D, Cardona JF, Usdan L, Ginis J, Mensa FJ, Zou J, Xie X, Shi PY, Lu C, Buitrago S, Scully IL, Cooper D, Koury K, Jansen KU, Türeci Ö, Şahin U, Swanson KA, Gruber WC, Kitchin N; C4591031 Clinical Trial Group. Winokur P, et al. Among authors: swanson ka. N Engl J Med. 2023 Jan 19;388(3):214-227. doi: 10.1056/NEJMoa2213082. N Engl J Med. 2023. PMID: 36652353 Free PMC article. Clinical Trial.
Adult vaccination.
Swanson KA, Schmitt HJ, Jansen KU, Anderson AS. Swanson KA, et al. Hum Vaccin Immunother. 2015;11(1):150-5. doi: 10.4161/hv.35858. Epub 2014 Nov 1. Hum Vaccin Immunother. 2015. PMID: 25483533 Free PMC article. Review.
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU. Mulligan MJ, et al. Among authors: swanson ka. Nature. 2020 Oct;586(7830):589-593. doi: 10.1038/s41586-020-2639-4. Epub 2020 Aug 12. Nature. 2020. PMID: 32785213 Clinical Trial.
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study.
Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Thompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Sahin U, Gruber WC. Walsh EE, et al. Among authors: swanson ka. medRxiv [Preprint]. 2020 Aug 28:2020.08.17.20176651. doi: 10.1101/2020.08.17.20176651. medRxiv. 2020. Update in: N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906 PMID: 32839784 Free PMC article. Updated. Preprint.
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Hilker R, Becker D, Eller AK, Grützner J, Boesler C, Rosenbaum C, Kühnle MC, Luxemburger U, Kemmer-Brück A, Langer D, Bexon M, Bolte S, Karikó K, Palanche T, Fischer B, Schultz A, Shi PY, Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL, Cutler M, Kalina W, Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Türeci Ö. Sahin U, et al. Among authors: swanson ka. Nature. 2020 Oct;586(7830):594-599. doi: 10.1038/s41586-020-2814-7. Epub 2020 Sep 30. Nature. 2020. PMID: 32998157 Clinical Trial.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Şahin U, Gruber WC. Walsh EE, et al. Among authors: swanson ka. N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14. N Engl J Med. 2020. PMID: 33053279 Free PMC article. Clinical Trial.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Polack FP, et al. Among authors: swanson ka. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. N Engl J Med. 2020. PMID: 33301246 Free PMC article. Clinical Trial.
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.
Xie X, Zou J, Fontes-Garfias CR, Xia H, Swanson KA, Cutler M, Cooper D, Menachery VD, Weaver S, Dormitzer PR, Shi PY. Xie X, et al. Among authors: swanson ka. bioRxiv [Preprint]. 2021 Jan 7:2021.01.07.425740. doi: 10.1101/2021.01.07.425740. bioRxiv. 2021. Update in: Nat Med. 2021 Apr;27(4):620-621. doi: 10.1038/s41591-021-01270-4 PMID: 33442691 Free PMC article. Updated. Preprint.
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Hilker R, Becker D, Eller AK, Grützner J, Boesler C, Rosenbaum C, Kühnle MC, Luxemburger U, Kemmer-Brück A, Langer D, Bexon M, Bolte S, Karikó K, Palanche T, Fischer B, Schultz A, Shi PY, Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL, Cutler M, Kalina W, Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Türeci Ö. Sahin U, et al. Among authors: swanson ka. Nature. 2021 Feb;590(7844):E17. doi: 10.1038/s41586-020-03102-w. Nature. 2021. PMID: 33469214 No abstract available.
106 results